885 related articles for article (PubMed ID: 35924475)
21. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
[TBL] [Abstract][Full Text] [Related]
23. Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.
Jäger M; Diem G; Sahanic S; Fux V; Griesmacher A; Lass-Flörl C; Wilflingseder D; Tancevski I; Posch W
J Infect Dis; 2023 Jul; 228(2):160-168. PubMed ID: 36869832
[TBL] [Abstract][Full Text] [Related]
24. Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study.
Kohmer N; Stein S; Schenk B; Grikscheit K; Metzler M; Rabenau HF; Widera M; Herrmann E; Wicker S; Ciesek S
Int J Infect Dis; 2023 Mar; 128():166-175. PubMed ID: 36587839
[TBL] [Abstract][Full Text] [Related]
25. The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.
Angkasekwinai N; Niyomnaitham S; Sewatanon J; Phumiamorn S; Sukapirom K; Senawong S; Toh ZQ; Umrod P; Somporn T; Chumpol S; Ritthitham K; Jantraphakorn Y; Srisutthisamphan K; Chokephaibulkit K
Asian Pac J Allergy Immunol; 2023 Jul; ():. PubMed ID: 37466962
[TBL] [Abstract][Full Text] [Related]
26. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
27. A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
Baek YJ; Kim WJ; Ko JH; Lee YJ; Ahn JY; Kim JH; Jang HC; Jeong HW; Kim YC; Park YS; Kim SH; Peck KR; Shin EC; Choi JY
Vaccine; 2023 Mar; 41(10):1694-1702. PubMed ID: 36754764
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Costa Clemens SA; Marchevsky N; Kelly S; Felle S; Eldawi A; Rajasingam R; Mahmud R; Lambe T; Voysey M; Gonzalez I; Milan EP; Justino MC; Bibi S; Aley P; Clemens R; Pollard AJ
Hum Vaccin Immunother; 2023 Aug; 19(2):2233400. PubMed ID: 37438960
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
[TBL] [Abstract][Full Text] [Related]
30. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3-4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination.
Assawakosri S; Kanokudom S; Suntronwong N; Chansaenroj J; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanathorn T; Klinfueng S; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Honsawek S; Poovorawan Y
Heliyon; 2024 Jan; 10(1):e23892. PubMed ID: 38226248
[TBL] [Abstract][Full Text] [Related]
32. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Madhi SA; Kwatra G; Richardson SI; Koen AL; Baillie V; Cutland CL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Ahmed K; Aley PK; Bhikha S; Bhorat AE; Esmail A; Horne E; Kaldine H; Mukendi CK; Madzorera VS; Manamela NP; Masilela M; Hermanus ST; Motlou T; Mzindle N; Oelofse S; Patel F; Rhead S; Rossouw L; Taoushanis C; van Eck S; Lambe T; Gilbert SC; Pollard AJ; Moore PL; Izu A
Lancet Infect Dis; 2023 Mar; 23(3):295-306. PubMed ID: 36273491
[TBL] [Abstract][Full Text] [Related]
33. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.
Chuang CH; Huang CG; Huang CT; Chen YC; Kung YA; Chen CJ; Chuang TC; Liu CC; Huang PW; Yang SL; Gu PW; Shih SR; Chiu CH
J Clin Virol; 2022 Dec; 157():105328. PubMed ID: 36399969
[TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
Front Immunol; 2022; 13():981693. PubMed ID: 36225911
[TBL] [Abstract][Full Text] [Related]
35. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.
Poh XY; Tan CW; Lee IR; Chavatte JM; Fong SW; Prince T; Hartley C; Yeoh AYY; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim C; Teo J; Lim DRX; Chia W; Hiscox JA; Ng LFP; Ren EC; Lin RTP; Renia L; Lye DC; Wang LF; Young BE
Clin Infect Dis; 2022 Dec; 75(12):2088-2096. PubMed ID: 35543372
[TBL] [Abstract][Full Text] [Related]
36. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
[TBL] [Abstract][Full Text] [Related]
37. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
van Gils MJ; Lavell A; van der Straten K; Appelman B; Bontjer I; Poniman M; Burger JA; Oomen M; Bouhuijs JH; van Vught LA; Slim MA; Schinkel M; Wynberg E; van Willigen HDG; Grobben M; Tejjani K; van Rijswijk J; Snitselaar JL; Caniels TG; ; Vlaar APJ; Prins M; de Jong MD; de Bree GJ; Sikkens JJ; Bomers MK; Sanders RW
PLoS Med; 2022 May; 19(5):e1003991. PubMed ID: 35580156
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.
Cohen G; Jungsomsri P; Sangwongwanich J; Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N
Hum Vaccin Immunother; 2022 Nov; 18(5):2052525. PubMed ID: 35323079
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations.
Sudjaritruk T; Mueangmo O; Saheng J; Winichakoon P; Salee P; Wongjak W; Chaito T; Praparattanapan J; Nuket K; Solai N; Wipasa J; Chawansuntati K; Chaiwarith R
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992147
[TBL] [Abstract][Full Text] [Related]
40. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
Cheng SMS; Mok CKP; Leung YWY; Ng SS; Chan KCK; Ko FW; Chen C; Yiu K; Lam BHS; Lau EHY; Chan KKP; Luk LLH; Li JKC; Tsang LCH; Poon LLM; Hui DSC; Peiris M
Nat Med; 2022 Mar; 28(3):486-489. PubMed ID: 35051989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
